尚太科技(001301.SZ):提前終止回購 已累計回購110.61萬股
格隆匯7月22日丨尚太科技(001301.SZ)公佈,截至公吿披露日,公司通過回購股份專用證券賬户以集中競價交易方式累計回購股份110.61萬股,佔公司目前總股本的0.4241%;購買股份的最高成交價為65.50元/股、最低成交價為51.83元/股,支付總金額為人民幣6936.76萬元(不含交易費用)。
截至公吿披露日,公司回購資金使用金額已達到最低限額,本次回購符合公司回購股份方案及相關法律法規的要求。鑑於公司本次回購股份數量已能夠滿足公司擬實施員工持股計劃及/或股權激勵的規模,公司經慎重考慮決定提前終止回購公司股份事項,自公司董事會決定終止本次回購方案之日起提前屆滿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.